BMEA Biomea Fusion Inc.

Biotech Analyst Ratings

Latest News

1. 20 May 2022 Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

   REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Biomea will attend the H.C. Wainwright Global Investment Conference virtually and will participate in 1x1 meetings held by the conference organizers.
   

   About Biomea Fusion

   Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that is designed to…

   View Full Article
2. 19 May 2022 Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

   • BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC₅₀ values across key FLT3 isoforms, potentially making it the most potent inhibitor of its class
     
   • Highly selective for FLT3, BMF-500 was observed to avoid other type III receptor tyrosine kinase (RTK) family members, including cKIT, which drives myelosuppression and limits utility of some first and second-generation FLT3 inhibitors
   • Initial in vivo studies demonstrated that BMF-500 elicited complete tumor regression of FLT3-ITD in mouse tumor models and maintained its effect without continued exposure
   • BMF-500 is potentially synergistic with BMF-219, Biomea's investigational covalent menin inhibitor currently in a Phase I clinical trial, COVALENT-101…

   View Full Article
3. 16 May 2022 Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights

   • COVALENT-101 study continues to enroll relapsed/refractory (R/R) acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients and has included R/R diffuse large B-cell lymphoma (DLBCL) and R/R multiple myeloma (MM) patients to the study. Company continues to explore indication expansion with the announced upcoming presentation of preclinical ex vivo data of BMF-219 in Chronic Lymphocytic Leukemia (CLL) at the American Society of Clinical Oncology (ASCO)
   • Presented preclinical validation data for BMF-219 in multiple solid and liquid tumor types at AACR 2022, with BMF-219 showing strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient-derived (PDX) models ex vivo including DLBCL, MM…

   View Full Article
4. 09 May 2022 Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference

   REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference. The fireside chat will take place on Wednesday, May 11^th at 4:00pm Pacific Time.
   

   A live webcast of the fireside chat can be accessed at https://investors.biomeafusion.com/ and will be available for 90 days following the presentation.

   About Biomea Fusion

   Biomea…

   View Full Article
5. 27 April 2022 Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

   • Biomea to present preclinical data in chronic lymphocytic leukemia (CLL) and Trial In Progress (TIP) information for its ongoing COVALENT-101 Phase I trial
     

   REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced the acceptance of two abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The 2022 ASCO annual meeting will be held from June 3-7, 2022, at McCormick Place in Chicago, IL.

   The titles of Biomea's accepted abstracts are listed below. Biomea will…

   View Full Article